Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Deals

Walvax Biotechnology Secures Exclusive Rights to Notitia’s Gut Microbiota Therapy

Fineline Cube May 26, 2025

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced an exclusive sublicense agreement with US-based Notitia...

Company Drug

Guangdong Zhongsheng Wins Peking University People’s Hospital Nod for RAY1225 Phase III Trials

Fineline Cube May 26, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Company Drug

Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer

Fineline Cube May 26, 2025

China-based Jiangxi Jemincare Group announced that it has received marketing approval from the National Medical...

Company Drug

Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial

Fineline Cube May 26, 2025

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...

Company Drug

GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma

Fineline Cube May 26, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that its Blenrep (belantamab mafodotin) has been...

Company Drug

Dizal Pharma Presents DZD8586 and DZD6008 Results at ASCO 2025

Fineline Cube May 26, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical results for its investigational...

Company Drug

Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Breakthrough Therapy Designation for HCC

Fineline Cube May 26, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that it has received Breakthrough Therapy...

Company Deals

Elpiscience Files for Hong Kong IPO Focusing on Immunotherapy Pipeline

Fineline Cube May 26, 2025

China-based Elpiscience Biopharmaceuticals, Inc. has filed for an initial public offering (IPO) with the Hong...

Company Deals

Medilink Therapeutics Collaborates with Wuhan Union Hospital on Clinical Trials

Fineline Cube May 26, 2025

Suzhou-based Medilink Therapeutics announced a clinical study collaboration agreement with Union Hospital, Tongji Medical College,...

Company Drug

Duality Biologics Receives FDA IND Approval for EGFR/HER3 ADC AVZO-1418

Fineline Cube May 26, 2025

Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United...

Company Drug

Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial

Fineline Cube May 26, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from...

Company Drug

Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals

Fineline Cube May 26, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency’s (EMA) Committee for...

Company Deals

Sichuan Kelun-Biotech Finalizes Licensing Deal for TSLP Monoclonal Antibody

Fineline Cube May 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received the upfront...

Company Drug

Roche’s Itovebi Recommended for EU Approval in PIK3CA-Mutated Breast Cancer

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its Itovebi (inavolisib) has been...

Company Medical Device

Jenscare Announces Positive 30-Day Results for LuX-Valve Plus in TRINITY Study

Fineline Cube May 26, 2025

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company Deals

Roche Partners with Broad Clinical Labs to Advance SBX Sequencing Technology

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced last week a strategic partnership with...

Company Drug

Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis

Fineline Cube May 26, 2025

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...

Company Medical Device

Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications

Fineline Cube May 26, 2025

US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA)...

Company Deals

Tonghua Dongbao to Sell Stake in Amoytop Biotech for USD 181 Million

Fineline Cube May 24, 2025

Chinese pharmaceutical firm Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) has announced plans to divest...

Company Deals

Shandong Boan Biotechnology Partners with HKUST for Biomedicine Innovation

Fineline Cube May 24, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has entered into a partnership with the...

Posts pagination

1 … 199 200 201 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.